Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Triaminic Allerchews With Loratadine Slated To Launch In 2004

This article was originally published in The Tan Sheet

Executive Summary

Novartis' Triaminic children's cough/coldline will be extended in early 2004 with Allerchews, the brand's first loratadine-containing offering. The product debuted at the National Association of Chain Drug Stores Marketplace in San Diego June 8-10

You may also be interested in...



Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2

Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year

Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2

Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year

Novartis OTC Business Makes Net Gains On Loratadine Sales In Q2

Novartis Consumer Healthcare's OTC unit is looking to its loratadine products to continue improving the division's net earnings for the remainder of the year

Related Content

Topics

UsernamePublicRestriction

Register

PS095590

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel